Fmr LLC Has $134.96 Million Holdings in Prothena Co. plc (NASDAQ:PRTA)

Fmr LLC increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA) by 0.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,066,983 shares of the biotechnology company’s stock after purchasing an additional 1,306 shares during the quarter. Fmr LLC owned approximately 0.15% of Prothena worth $134,961,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in PRTA. Signaturefd LLC boosted its stake in shares of Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock worth $28,000 after buying an additional 863 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Prothena by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 4,026 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Prothena during the 3rd quarter worth approximately $210,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Prothena by 13.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 1,186 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Prothena by 26.0% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 14,039 shares of the biotechnology company’s stock valued at $348,000 after buying an additional 2,895 shares during the last quarter. Institutional investors own 97.08% of the company’s stock.

Prothena Trading Down 8.1 %

Prothena stock opened at $13.78 on Wednesday. The company has a market capitalization of $741.49 million, a price-to-earnings ratio of -5.56 and a beta of 0.09. The stock’s 50 day moving average is $16.77 and its 200-day moving average is $19.76. Prothena Co. plc has a 12 month low of $13.22 and a 12 month high of $41.54.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $1.22 million. During the same quarter last year, the business earned $0.38 EPS. The company’s quarterly revenue was down 98.9% compared to the same quarter last year. As a group, equities research analysts predict that Prothena Co. plc will post -2.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PRTA has been the topic of several analyst reports. Oppenheimer dropped their price target on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. Bank of America dropped their target price on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating on the stock in a report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and set a $84.00 price target on shares of Prothena in a report on Wednesday, November 13th. Royal Bank of Canada cut their price objective on Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Finally, StockNews.com lowered Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Prothena presently has an average rating of “Moderate Buy” and an average price target of $61.86.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.